Giselle M. Boukhaled

Toronto, ON M5G2M9, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 24 publications

CD28-driven ex vivo generation of stem-like memory CD8+ T cells bypassing CD3/TCR signaling.

CD28-driven ex vivo generation of stem-like memory CD8+ T cells bypassing CD3/TCR signaling.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: April 21, 2026

Type I interferons enhance B cell activation and promote differentiation of double negative 2 cells in SLE.

Type I interferons enhance B cell activation and promote differentiation of double negative 2 cells in SLE.

Journal: Lupus science & medicine

Published: March 06, 2026

CAR T Cells Targeting an Intracellular Leukemia Antigen Promiscuously Presented by Diverse HLA-II Alleles.

CAR T Cells Targeting an Intracellular Leukemia Antigen Promiscuously Presented by Diverse HLA-II Alleles.

Journal: Blood cancer discovery

Published: June 23, 2025

Pembrolizumab and stereotactic body radiotherapy combined in advanced hepatocellular carcinoma post sorafenib - A phase II trial (PEMRAD).

Pembrolizumab and stereotactic body radiotherapy combined in advanced hepatocellular carcinoma post sorafenib - A phase II trial (PEMRAD).

Journal: JHEP reports : innovation in hepatology

Published: May 05, 2025

Cross-Cancer Analysis Reveals a Distinct Pattern of Immune Modulation During Curative Radiation Therapy.

Cross-Cancer Analysis Reveals a Distinct Pattern of Immune Modulation During Curative Radiation Therapy.

Journal: International journal of radiation oncology, biology, physics

Published: April 03, 2025

Microbial Ecosystem Therapeutics 4 (MET4) elicits treatment-specific IgG responses associated with changes in gut microbiota in immune checkpoint inhibitor recipients with advanced solid tumors.

Microbial Ecosystem Therapeutics 4 (MET4) elicits treatment-specific IgG responses associated with changes in gut microbiota in immune checkpoint inhibitor recipients with advanced solid tumors.

Journal: Journal for immunotherapy of cancer

Published: March 06, 2025

IL-2 produced by HBV-specific T cells as a biomarker of viral control and predictor of response to PD-1 therapy across clinical phases of chronic hepatitis B.

IL-2 produced by HBV-specific T cells as a biomarker of viral control and predictor of response to PD-1 therapy across clinical phases of chronic hepatitis B.

Journal: Hepatology communications

Published: August 31, 2023

Molecular, metabolic and functional CD4 T cell paralysis impedes tumor control.

Molecular, metabolic and functional CD4 T cell paralysis impedes tumor control.

Journal: bioRxiv : the preprint server for biology

Published: May 03, 2023

Molecular, metabolic, and functional CD4 T cell paralysis in the lymph node impedes tumor control.

Molecular, metabolic, and functional CD4 T cell paralysis in the lymph node impedes tumor control.

Journal: Cell reports

Published: November 23, 2022

Mass cytometry immunostaining protocol for multiplexing clinical samples.

Mass cytometry immunostaining protocol for multiplexing clinical samples.

Journal: STAR protocols

Published: September 02, 2022

Pre-encoded responsiveness to type I interferon in the peripheral immune system defines outcome of PD1 blockade therapy.

Pre-encoded responsiveness to type I interferon in the peripheral immune system defines outcome of PD1 blockade therapy.

Journal: Nature immunology

Published: July 19, 2021

Dynamic CD4+ T cell heterogeneity defines subset-specific suppression and PD-L1-blockade-driven functional restoration in chronic infection.

Dynamic CD4+ T cell heterogeneity defines subset-specific suppression and PD-L1-blockade-driven functional restoration in chronic infection.

Journal: Nature immunology

Published: December 08, 2020

Showing 1-12 of 24

Last Updated: 09/26/2026